Insights on the Biobanks Global Market to 2027 – Regenerative Medicine Applications for Biobanking Market will Drive Growth – ResearchAndMarkets.com -…

DUBLIN--(BUSINESS WIRE)--The "Biobanks Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2017-2027 Segmented By Type, By Sample Type, By Application, By End User, By Region" report has been added to ResearchAndMarkets.com's offering.

The Global Biobanks Market stood at USD40.70 billion in 2021 and is expected to grow at an impressive rate of 8.22% during the forecast period. This can be ascribed to the growing investments and research & development in advanced therapies such as cancer genomic studies, personalized medicine, among others.

Biobanks play a pivotal role in disease diagnosis and development of a treatment or drug. The COVID-19 pandemic crisis has significantly increased the demand for biobanks worldwide. During the pandemic crisis various new specialized biobanks, focusing on COVID-19 were developed for research & development activities. For instance, in July 2021, Tulane University announced a new COVID-19 biobank containing blood & cell samples from survivors.

Regenerative Medicine Applications for Biobanking Market will drive the Market

Biobanks Market contributes to the advancement of biomedical and translational research by collecting and preserving biological samples such as blood, tissues, and nucleic acids, which are then made available for use in research to discover disease-relevant biomarkers; this information is then used for diagnosis, prognosis, and drug response prediction.

The increase in the number of research activities in this area is a major market driver. The availability of government financing for regenerative medicine, stem cell treatments, and cell and gene therapy are fueling this segment's research. Aside from that, the growing trend of cord blood banking will help this market segment develop. Future possibilities are predicted to include breakthroughs in orthopaedic therapies utilising stem cells.

Stakeholders Shifting Focus from Sample-driven to Data-driven Strategies

Precision medicine research is gaining traction as a result of the digital revolution. Precision medicine research and clinical data are also inextricably linked. Although there are times when there are modest connections between the two variables. Because the availability of data on well-characterized and high-quality samples is of relevance to healthcare organizations, this works as a profitable opportunity for stakeholders in the biobanking market.

Artificial intelligence (AI) and big data analytics are being introduced into the biobanking landscape in order to develop strong correlations between precision medicine research and clinical data. This has aided faster research, which has had a positive impact on the delivery of new pharmaceuticals in the healthcare industry. As a result, there is a growing demand in the biobanking industry for increased informatics capabilities.

Demand for Temperature Control Systems to Gain Strength in Biobanks Market

Biobanks are in high demand to preserve a variety of biospecimen, from blood to tissues, cells, and nucleic acids, due to the growing trend of personalized treatments to reduce chronic disease-related mortality rates.

As major manufacturers are focusing their efforts on the release of freezers and refrigerators, cryogenic storage systems, and other equipment for the storage of biobank samples, the market is expected to place a greater emphasis on temperature control systems, boosting global demand for Biobanks. The equipment segment is being driven by an increase in the number of Biobanks in several countries, as well as a desire for sophisticated biobanking equipment.

Companies Mentioned

Report Scope:

In this report, the Global Biobanks Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Biobanks Market, By Type:

Global Biobanks Market, By Sample Type

Global Biobanks Market, By Application:

Global Biobanks Market, By End-User:

Global Biobanks Market, By Region:

For more information about this report visit https://www.researchandmarkets.com/r/x26mlq

Read more from the original source:
Insights on the Biobanks Global Market to 2027 - Regenerative Medicine Applications for Biobanking Market will Drive Growth - ResearchAndMarkets.com -...

Cell-free Protein Expression Market to be Worth $475.1 Million by 2030 – Grand View Research, Inc. – Yahoo Finance

SAN FRANCISCO, Sept. 26, 2022 /PRNewswire/ -- The global cell-free protein expression market share is expected to reach USD 475.1 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.48% from 2022 to 2030. Growing demand for novel biologic products for the treatment of severe chronic diseases such as, cancer, multiple sclerosis, and anemia is a major factor contributing to the market growth. For instance, as reported by the world health organization (WHO) in 2020, there were 10 million deaths or about 1 in 6 deaths due to cancer making it to be one of the major causes of death worldwide. Such rising cancer incidences are increasing the adoption of protein biologics as an alternative treatment option due to their target-specific treatment with fewer side effects compared to other treatments which is positively impacting the market growth.

Grand View Research, Inc., Logo

Funding in genomic sciences and precision medicine R&D is aiding the market growth. For instance, in May 2022, the Medical College of Wisconsin's Center for Genomic Sciences and Precision Medicine received USD 10 million funding for exploring genomic applications for the treatment of various rare and undiagnosed diseases. Moreover, investments by government initiatives are advancing and expanding the R&D activities of proteomics. For instance, in August 2020, the National Institutes of Health granted a $10.6 Million Federal Grant to the University of Arkansas for Medical Sciences to expand its proteomic resources. Similarly, in June 2022 British Columbia government invested and is managing large-scale genomics and proteomics research projects based on health, forestry, and agriculture among others. Thus, such funding initiatives are expected to boost the adoption of the proteomics and genomics in R&D and fuel the market growth during the forecast period.

Key Industry Insights & Findings from the report:

By product, the expression systems segment held the largest share of the cell-free protein expression market. E. coli lysates is one of the most preferred lysates commercially due to cost-effectiveness and higher protein yield.

The wheat germ cell-free protein expression system segment is expected to grow lucratively over the forecast period. This system is a choice of preference for numerous applications in protein research comprising options for protein labeling and the expression of proteins such as multiple protein complexes and membrane proteins.

By application, the enzyme engineering segment held a larger share of the global market. Enzyme engineering plays an important role in bio manufacturing synthetic biology, and medicine.

The transcription & translation systems segment by method captured the highest revenue share of the market in 2021. Coupled transcription and translation (TNT) systems offer investigators time-saving options for eukaryotic in vitro transcription and translation, by connecting these processes in a single tube format.

By end-user, the pharmaceutical & biotechnological companies segment held a larger share in 2021, owing to the expansion of the current manufacturing capacities coupled with increasing prevalence of chronic disease which in turn demands for novel therapeutic drugs.

North America dominated the global market in 2021 due to the growth in the biotechnology and pharmaceutical industry, presence of high research and development investment, and the development of novel cell-free protein engineering products in the region.

The Asia Pacific is expected to grow considerably in the future increasing investments by major market players coupled with funding by the government for R&D.

A few of the key market players include Thermo Fisher Scientific, Inc,Takara Bio Company, New England Biolabs, Merck KGaA and others.

Read 160-page market research report, "Cell-free Protein Expression Market Size, Share & Trends Analysis Report By Product (Expression Systems, Reagents), By Application (Enzyme Engineering, Protein Labeling), By Method, By End-use, By Region And Segment Forecasts, 2022 - 2030", published by Grand View Research.

Cell-free Protein Expression Market Growth & Trends

Moreover, the surge in infectious diseases such as lower respiratory infections and human immunodeficiency virus (HIV), among others in recent years due to climate change, changing land-use patterns, and rapid urbanization are expected to aid in the market growth. For instance, according to WHO, lower respiratory infections ranked fourth place in causing deaths globally. In addition, in 2020, according to UNAIDS there were approximately 38.4 million people across the globe with HIV. Thus, the rise in infectious diseases require effective diagnosis and treatment options such as CFPE in the market. For instance, CFPE based system can be activated in less time by adding water. This feature helps in the portable diagnosis of infectious diseases. Therefore, rising infectious diseases can increase the applications of CFPS in treatment and diagnosis, and are likely to contribute to the market growth in the near future.

The development of vaccines and treatment was an emergency requirement globally to treat and combat the spread of COVID-19 infection. The low-cost, rapid manufacture and production of therapeutic antibodies were expected in the market. The conventional method of manufacturing antibodies relied on cell-based protein expression and this production required nine months or more. The CFPE-based vaccine production cut the time from a few months to one month or a few weeks. For instance, SwiftSacle Biologics, cell-free lysate-derived E. coli bacteria shrank the timeline of vaccine production from nine months to one month and turned out to be a game changer during the pandemic. Therefore, the CFPS advantages over traditional cell-based methods increased the applications of CFPS in the industries during COVID-19 and led to a boost in the market growth.

The increase in investments by various pharmaceuticals, biopharmaceutical companies is increasing the R&D activities of genomics & proteomics in drug development. For instance, Thermo Fisher Scientific invested in a spatial proteomics Ionpath firm to scale up the MIBIscope instruments and end-to-end spatial proteomics services to meet the increasing demand for services. In addition, in Jan 2022, Protai received funding of $8 million to provide an AI-based proteomics platform. This effective approach improved the development process and accuracy of drug discovery by saving time and lowering the costs of R&D. Such R&D investments increased the adoption of proteomics and genomics and are expected to contribute to the market growth.

On the other hand, Cell-free protein expression turns costly in the up scaled experiments due to the complexity of the cell-free lysates from the eukaryotic sources and the challenges in post-translational modifications of biomolecules due to misfolding or pleiotropic interactions with cellular components. The CFPE offers low protein production that can be used in small scale production and turns expensive for large scale production in industries. For instance, as per a research article published in the Journal of visualize experiments in Feb 2019, commercial CFPS kits, such as iPE-Quick Kit (Sigma-Aldrich) cost around USD 0.82 per microgram of protein, while Expressway (Thermo Fisher) costs about USD 0.76 per microgram of protein, excluding the cost of labor and equipment. Therefore, CFPE is expensive in large scale production and can impede the market growth.

Cell-free Protein Expression Market Segmentation

Grand View Research has segmented the global cell-free protein expression market based on product, application, method, end-use, and region:

Cell-free Protein Expression Market - Product Outlook (Revenue, USD Million, 2018 - 2030)

Expression Systems

E. coli Cell-free Protein Expression System

Wheat Germ Cell-free Protein Expression System

Rabbit Reticulocytes Cell-free Protein Expression System

Insect Cells Cell-free Protein Expression System

Human Cell-free Protein Expression System

Others

Reagents

Cell-free Protein Expression Market - Application Outlook (Revenue, USD Million, 2018 - 2030)

Cell-free Protein Expression Market - Method Outlook (Revenue, USD Million, 2018 - 2030)

Cell-free Protein Expression Market - End-User Outlook (Revenue, USD Million, 2018 - 2030)

Cell-free Protein Expression Market - Regional Scope Outlook (Revenue, USD Million, 2018 - 2030)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

List of Key Players of Cell-free Protein Expression Market

Thermo Fisher Scientific, Inc.

Takara Bio Company

Merck KGaA

New England Biolabs

Promega Corporation

Jena Bioscience GmbH

GeneCopoeia, Inc.

Biotechrabbit GmbH

Cube Biotech GmbH

CellFree Sciences Co., Ltd.

Check out more related studies published by Grand View Research:

Cell Culture Protein Surface Coating Market - The global cell culture protein surface coating market size is expected to reach USD 2.5 billion by 2030, registering a CAGR of 15.2% from 2022 to 2030, according to a new report by Grand View Research, Inc. Increasing focus on stem cell research and development is the most crucial factor that drives the industry growth.

Protein Labeling Market - The global protein labeling market size is expected to reach USD 4.11 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.6% from 2022 to 2030. The study of Post-translational Modification (PTM) of proteins has gained immense popularity in cell biology and disease treatment and prevention.

Cell Line Development Market - Global cell line development market size is expected to reach USD 6.24 billion by 2022, according to a new report by Grand View Research, Inc. The Increasing demand for monoclonal antibodies and patent expiration of blockbuster biologics are expected to drive the cell line development industry over the forecast period.

Browse through Grand View Research's Biotechnology Industry Research Reports.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James Corporate Sales Specialist, USA Grand View Research, Inc. Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: sales@grandviewresearch.com Web: https://www.grandviewresearch.com Grand View Compass| Astra ESG Solutions Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg

Cision

View original content:https://www.prnewswire.com/news-releases/cell-free-protein-expression-market-to-be-worth-475-1-million-by-2030---grand-view-research-inc-301632900.html

SOURCE Grand View Research, Inc.

More here:
Cell-free Protein Expression Market to be Worth $475.1 Million by 2030 - Grand View Research, Inc. - Yahoo Finance

Tryp Therapeutics Strengthens Intellectual Property Portfolio with Provisional Patent Applications for Fibromyalgia Treatment and for Crystalline…

KELOWNA, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the filing of two new provisional patent applications. One patent application, #63/405,786, is for the use of psilocybin for the treatment of patients with fibromyalgia and the other application, #63/375,305, expands the IP related to the Company’s development of TRP-8803.

See original here:
Tryp Therapeutics Strengthens Intellectual Property Portfolio with Provisional Patent Applications for Fibromyalgia Treatment and for Crystalline...

Neuronetics Launches Innovations To NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform

Upgrades will enhance and automate the patient candidate experience for all NeuroStar providers, leading to faster patient identification of those in need of treatment Upgrades will enhance and automate the patient candidate experience for all NeuroStar providers, leading to faster patient identification of those in need of treatment

See the article here:
Neuronetics Launches Innovations To NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform

Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022

ISELIN, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it will present at Eyecelerator @ AAO 2022 taking place Thursday, September 29, 2022 in Chicago, Illinois.

See the original post here:
Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022

Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil

NEW YORK, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Adium Pharma S.A. (“Adium”) has submitted a regulatory filing for DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma to the Brazilian Health Regulatory Agency, Agência Nacional de Vigilância Sanitária (“Anvisa”).

Excerpt from:
Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil

Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe…

SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that the company has completed enrollment of its latest Phase 2 clinical study of RTX for treating moderate-to-severe osteoarthritis of the knee pain (OAK).

View post:
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe...

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2022 Financial Results on November 9, 2022

CANTON, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that third quarter of fiscal year 2022 financial results will be reported after the market closes on Wednesday, November 9th.

Original post:
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2022 Financial Results on November 9, 2022

RS BioTherapeutics Secures $3 Million Seed II Round of Funding

CUMBERLAND, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and commercialize interventions to address chronic and acute pulmonary (lung) inflammation-based diseases, is pleased to announce that is has secured a $3 million Seed II round of funding.

Visit link:
RS BioTherapeutics Secures $3 Million Seed II Round of Funding

BlueSphere Bio Presents Data Demonstrating Efficiency of Parallel TCR Capture and Bioinformatics Platforms at 7th Annual CAR-TCR Summit

Parallel processing using TCXpress™ and iTCXpress™ platforms significantly increases throughput, reduces the cost and shortens the timing of identifying novel TCRs Parallel processing using TCXpress™ and iTCXpress™ platforms significantly increases throughput, reduces the cost and shortens the timing of identifying novel TCRs

Continued here:
BlueSphere Bio Presents Data Demonstrating Efficiency of Parallel TCR Capture and Bioinformatics Platforms at 7th Annual CAR-TCR Summit